Summary

Laboratory testing as a part of laboratory in vitro diagnostic (IVD) has become required tool in clinical practice for diagnosing, monitoring and prognosis of diseases, as well as for prediction of treatment response. The number of IVD tests available in laboratory practice has increased over the past decades and is likely to further increase in the future. Consequently, there is growing concern about the overutilization of laboratory tests and rising costs for laboratory testing. It is estimated that IVD accounts for between 1.4 and 2.3% of total healthcare expenditure and less than 5% of total hospital cost (Lewin Group report). These costs are rather low when compared to pharmaceuticals and medical aids which account for 15 and 5%, respectively. On the other hand, IVD tests play an important role in clinical practice, as they influence from 60% to 70% of clinical decision-making. Unfortunately, constant increases in healthcare spending are not directly related to healthcare benefit. Since healthcare resources are limited, health payers are interested whether the benefits of IVD tests are actually worth their cost. Many articles have introduced frameworks to assess the economic value of IVD tests. The most appropriate tool for quantitative assessment of their economic value is cost-effectiveness (CEA) and cost-utility (CUA) analysis. The both analysis determine cost in terms of effectiveness or utilities (combine quantity and quality of life) of new laboratory test against its alternative. On the other hand, some investigators recommended calculation of laboratory test value as product of two ratios: Laboratory test value = (Technical accuracy/Turnaround time) ×...
(Utility/Costs). Recently, some researches used multicriteria decision analysis which allows comparison of diagnostic strategies in terms of benefits, opportunities, costs and risks. All analyses are constructed to identify laboratory test that produce the greatest healthcare benefit with the resources available. Without solid evidence that certain laboratory tests are cost-effective, laboratory services cannot be improved. Consequently, simple policy measures such as cost cutting may be imposed upon many laboratories while patients will have limited access to laboratory service.

**Keywords:** laboratory tests, cost-effectiveness, cost-utility, multicriteria decision analysis

### Introduction

Laboratory *in vitro* diagnostic (IVD) tests, two- and three-dimensional imaging and various types of endoscopy are examples of diagnostic technologies. They form an integral part of effective healthcare systems by providing essential information for medical decision-making, from personalised cancer treatment to treatment of infections by the appropriate antibiotic selection (1). IVD tests use samples for example blood, urine and tissue that have been taken from the human body in order to assess the potential risk of developing a disease, monitor disease progression, treatment response, efficacy of therapy and to medicate patients with specific drugs and therapies (2). The demand for quicker and more accurate medical diagnostics, including IVD tests, is rising. Improving the accuracy and efficiency of testing provides a substantial contribution to healthcare resource saving. As a consequence, the number of IVD tests available in laboratory practice has increased over the past decades and is likely to further increase in the future.

It is estimated that IVD accounts for between 1.4 and 2.3% of total healthcare expenditure (3, 4) and less than 5% of total hospital cost (Lewin Group report) (5). These costs are rather low when compared to pharmaceuticals and medical aids which account for 15 and 5%, respectively (6). According to Serbian Health Insurance Fund data, in 2016 IVD tests, consumables and medical supplies accounted 21% of total healthcare expenditure, respectively (7). Despite the fact that laboratory tests form a very small part of total healthcare expenditure they exert a great influence on medical decisions (8).

Unfortunately, constant increases in healthcare spending are not directly related to healthcare benefit. There is a great deal of evidence to suggest that costs due to over-utilization (9), errors (10), unnecessary or inappropriate test utilization and unnecessary test repetition (11) accounted for expenses much higher than those due to the direct costs of appropriate laboratory tests (12). In addition, a British study has estimated that eliminating inappropriate testing could save the National Health Service up to £1 billion in test costs alone (13). On the other hand, the growing number of laboratory tests in recent years has created challenges for physicians and laboratory professionals to determine the best strategy to diagnose disease, monitor disease progression and monitor treatment response. In many cases laboratory professionals make choices between two or more laboratory tests with similar diagnostic importance but with different associated costs without supporting data from comparative research studies. An apparently expensive test might turn out to be cost-saving if it averts costly procedures and/or therapy. Since healthcare resources are limited, health payers are interested whether the benefits of IVD tests are actually worth their cost.

### Problems in implementing economic evaluation of laboratory testing

For many years in the European Union only the CE label was required for diagnostic test registration. However, in the light of financial constraints third-party payers need to be sure that CE-labelled diagnostics tests have realistic pricing and/or add true value to society’s healthcare (14).

Many articles have introduced frameworks to assess the economic value of IVD tests. The most appropriate tool for quantitative assessment of their economic value is cost-effectiveness (CEA) and cost-utility (CUA) analysis. Both analyses compare the costs and effectiveness/utility of two or more health interventions, for example IVD tests (15). Potential usefulness from IVD testing is early and accurate diagnosis, appropriate patient selection for therapy and consequently increasing patients’ life expectancy and quality of life. Therefore, utility in CUA is frequently expressed as quality-adjusted life-years (QALY) (15). Unfortunately, this value is rarely available for IVD tests. In cross-sectional or cohort studies test accuracy is the most accessible value. However,
this value is a surrogate for patient-important outcomes, as studies often provide low-quality evidence for IVD test utility (16). In addition, decision makers face problems in interpreting diagnostic accuracy. It is necessary to present and interpret the results so that clinicians, policy makers, consumers, and other researchers can perfectly understand them. In such situations, Van den Bruel and colleagues recommended an investigation into the test’s influence on physicians’ opinions about diagnosis (17). Such evidence may be used for CEA of IVD tests in an early stage of an investigation. On the other hand, utility value should also be determined by expert elicitation (18).

An additional problem in IVD economic evaluation by CEA and CUA is lack of an appropriate threshold value. An intervention is considered to be “cost-effective” if the cost effectiveness ratio is below the threshold (19). However, it is difficult to estimate the thresholds at which IVD tests are effective enough to justify funding. The UK National Institute for Health and Care Excellence (NICE) recently recommended cost-effectiveness threshold in a range from £20,000 to £30,000 per QALY for drugs (20). Unfortunately, this threshold massively exceeds the cost of conventional diagnostic testing (21). Alternatively, in low and middle income countries the World Health Organization (WHO) has recommended thresholds of 1 to 3 times the gross domestic product per capita (22). However, the consequence of threshold use, if it is an inappropriate measure of the health cost, is that thresholds are likely to reduce, rather than increase, population health. Up to now CEA and CUA have only been employed towards a limited number of diagnostics.

### Additional recommendations for laboratory test economic evaluation

To avoid such a problem, calculation of laboratory test value as a product of two ratios, test performance and efficiency has been recommended by Equation:

\[
\text{Laboratory test value} = \left( \frac{\text{Technical accuracy}}{\text{Turnaround time}} \right) \times \left( \frac{\text{Utility}}{\text{Costs}} \right)
\]

Good test performance is associated with high accuracy and low turnaround time, while high efficiency is associated with a high percentage of clinical decisions made (clinical utility) over costs. In this case, utility represents the most accurate conclusion given the available evidence for a diagnostic test (23).

In addition, healthcare decisions should be based on a broad range of variables that are not part of the CEA, CUA or laboratory test value model such as clinical accuracy, number of both false and true positive and negative values, priorities, accessibility and ease of use (24). In the laboratory/hospital context multiple criteria should be considered simultaneously when deciding whether or not to adopt a new laboratory test. Recently, some investigators have used multi-criteria decision analysis (MCDA) methodology. In MCDA each criterion is scored and weighted (25). Scores represent ranked alternatives for each criterion. Weights for each of the criteria reflect their relative importance to the decision. They represent the opinion of a single decision maker or combine opinions of a group of experts. A mathematical equation combines these two components and the result is overall weighted scores that provide an overall assessment of each alternative, Table I (25).

| Criterion | Alternative 1 | Alternative 2 | Alternative f |
|-----------|---------------|---------------|---------------|
| Weight1   | Criterion 1   | S11           | /             | S1f           |
| Weight2   | Criterion 2   | /             | /             | /             |
| Weight3   | Criterion 1   | S11           | /             | S1f           |
|           |               | OWF1          | OWF2          | OWFn          |

Criterion 1 – Criterioni (rows) and Alternative 1 – Alternative f (columns) represent the criteria and alternatives, respectively. The score Siv describes the performance of Alternativef against Criteriai. A higher score value means a better performance. Weight1 – Weighti reflect the relative importance of Criteriai to the decision. The overall weighted scores (OWF) are the final ranking values of the alternatives. The alternative with the highest OWF value is the best of the alternatives.

Examples of laboratory test economic evaluation

The goal of an effective and efficient laboratory is to identify laboratory tests that create the greatest healthcare benefit with the resources available. In addition, overuse, underuse and misuse of laboratory testing should be minimized. An example of cost-effective laboratory test selection was described by Petrovic and coworkers (27). They created the decl-
sion analytical model to describe different strategies for acute kidney injury diagnosis in children after cardiac surgery using monitoring of creatinine (standard monitoring) and new biomarkers [serum cystatin C (sCys C), urine neutrophil gelatinase-associated lipocalin (uNGAL) and urine liver fatty acid-binding protein (uL-FABP)]. Tests for uNGAL and sCys C were associated with higher costs and lower effectiveness compared to uL-FABP. The use of uL-FABP would likely represent an economically advantageous strategy for early diagnosis of child acute kidney injury after cardiac surgery. Another example of CEA application by laboratory professionals as a tool for avoiding inappropriate test utilization examined the cost-effectiveness of two different strategies for screening of deep vein thrombosis (DVT) with three different D-dimer assays (Innovance D-dimer, Hemosil D-dimer HS and Vidas D-dimer Exclusion II) (28). One strategy included assessment of clinical probability for DVT (PTP) and another strategy excluded PTP assessment. CEA indicated an advantage of D-dimer measurements in combination with PTP assessment over D-dimer measurements without PTP. For laboratories assessing high numbers of DVT patients, the best cost-effectiveness ratio was for the diagnostic strategy which employed the Vidas D-dimer Exclusion II assay. In contrast, the Hemosil D-dimer HS assay was the most cost effective strategy for laboratories with a small number of DVT patients.

Conclusion

In summary, IVD testing can reduce both direct and indirect healthcare costs if it results in more accurate and timely medical diagnoses. However, without solid evidence that certain laboratory tests are cost-effective, laboratory services cannot be improved. Harsh across-the-board cost cutting of laboratory services will limit the diagnoses of patients as a reduced number of tests will be available. Therefore, determining cost-effectiveness prior to cost cutting is much more logical but requires extensive education of both laboratory professionals and non-clinical laboratory staff in order to determine which tests will remain and which will be omitted from the laboratory test portfolio.

Acknowledgements

The work was financially supported by the Ministry of Education, Science and Technological Development, Republic of Serbia (Project No. 175035).

Conflict of interest statement

The authors stated that they have no conflicts of interest regarding the publication of this article.

References

1. National Institute for Health and Care Excellence. Diagnostics Assessment Programme. Available: https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-diagnostics-guidance
2. Raman G, Avendano E, Chen M. Update on Emerging Genetic Tests Currently Available for Clinical Use in Common Cancers, in Technology Assessment Report. Rockville, MD: Agency for Healthcare Research and Quality; 2013.
3. Rohr UP, Binder C, Dieterle T, Giusti F, Messina CG, Toerien E, et al. The value of in vitro diagnostic testing in medical practice: a status report. PLoS One 2016; 11: e0149856.
4. Lippi G, Mattiuzzi C. Testing volume is not synonymous of cost, value and efficacy in laboratory diagnostics. Clin Chem Lab Med 2013; 51: 243–5.
5. The Lewin Group, Inc. The value of diagnostics innovation, adoption and diffusion into health care; 2003. Available: http://www.lewin.com/content/dam/Lewin/Resources/Site Sections/Publications/ValueofDiagnostics.pdf
6. Health expenditures in Germany as share of GDP and in millions of Euro (absolute and per inhabitant). Health expenditure, time series. Available: http://www.gbe-bund.de/gbe10/trecherche/prc_them_rech?tk=19200 &tk2=19300&p_uid=gast&p_aid=71688746&p_sprache=E&cnt nt=10&out=19310
7. National Health Insurance Fund. Predra un sredstava zdravstvenim ustanovama primarne, sekundarne I terci-jarne zdravstvene za{tite za 2017. godinu. Available: http://www.rfzor.rs/download/pravilnici/ugovaranje/Pri log%201-16052017.pdf
8. Wilke MH, Schenker M, Hoffmann G. Detection and documentation of DRG-relevant comorbidities using laboratory tests. Aust Health Rev 2002; 25: 152–60.
9. Lewandrowski K. Managing utilization of new diagnostic tests. Clin Leadersh Manag Rev 2003; 17: 318–24.
10. Hammerling JA. A Review of Medical Errors in Laboratory Diagnostics and Where We Are Today. Lab Med 2012; 43(2): 41–4.
11. Zhi M, Ding EL, Theisen-Toupal J, Whelan J, Arnaout R. The landscape of inappropriate laboratory testing: a 15-year meta-analysis. PLoS One 2013; 8(11):e78962.
12. Plebani M, Panteghini M. Promoting clinical and laboratory interaction by harmonization. Clin Chim Acta 2014; 432: 15–21.
13. Fryer AA, Hanna PW. Managing demand for pathology
tests: financial imperative or duty of care? Ann Clin Biochem 2009; 46: 435–7.

14. Miller I, Ashton-Chess J, Spolders H, Fert V, Ferrara J, Kroll W, et al. Market access challenges in the EU for high medical value diagnostic tests. Personalized Medicine 2011; 8: 137–48.

15. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press, 1996.

16. Atkins D, Briss PA, Eccles M, Flottorp S, Guyatt GH, Harbour RT, Hill S, Jaeschke R, Liberati A, Magrini N, Mason J, O’Connell D, Oxman AD, Phillips B, Schümann H, Edejer TT, Vist GE, Williams JW Jr; GRADE Working Group. Systems for grading the quality of evidence and the strength of recommendations II: pilot study of a new system. BMC Health Serv Res 2005; 5(1): 25.

17. Van den Bruel A, Cleemput I, Aertgeerts B, Ramaekers D, Buntinx F. The evaluation of diagnostic tests: evidence on technical and diagnostic accuracy, impact on patient outcome and cost-effectiveness is needed. J Clin Epidemiol 2007; 60(11): 1116–22.

18. Bojke L, Claxton K, Bravo-Vergel Y, Sculpher M, Palmer S, Abrams K. Eliciting distributions to populate decision analytic models. Value Health 2010; 13(5): 557–64.

19. Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 2008; 8: 165–78.

20. Appleby J. Crossing the line: NICE’s value for money threshold. BMJ 2016;352: i1336.

21. Su B-G, Chen S-F, Yeh S-H, Shih P-W, Lin C-C. Cost evaluation of clinical laboratory in Taiwan’s National Health System by using activity-based costing. Clin Chem Lab Med 2016; 54: 1753–8.

22. World Health organization. Commission on Macroeconomics and Health. Available: http://apps.who.int/iris/bitstream/10665/42435/1/924154550X.pdf

23. Durtschi A, Julicher P. Assessing the value of cardiac biomarkers: going beyond diagnostic accuracy? Future Cardiol 2014; 10: 367–80.

24. Wiseman V, Mitton C, Doyle-Waters M, Drake T, Conteh L, Newall AT, Onwujekwe O, Jan S. Using Economic Evidence to Set Healthcare Priorities in Low-Income and Lower-Middle-Income Countries: A Systematic Review of Methodological Frameworks. Health Econ 2016; 25 Suppl 1: 140–61.

25. Thokala P, Duenas A. Multiple criteria decision analysis for health technology assessment Value Health 2012; 15 (8): 1172–81.

26. Theodorsson E. Quality assurance in clinical chemistry: a touch of statistics and a lot of common sense. J MEd Biochem 2016; 35: 105–12.

27. Petrovic S, Bogavac-Stanojevic N, Lakic D, Peco-Antic A, Vulicevic I, Ivanisevic I, Kotur-Stevuljevic J, Jelic-Ivanovic Z. Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery. Biochemia Medica 2015; 25 (2): 262–71.

28. Bogavac-Stanojevic N, Dopsaj V, Jelic-Ivanovic Z, Lakic D, Vasic D, Petrova G. Economic evaluation of different screening alternatives for patients with clinically suspected acute deep vein thrombosis. Biochemia Medica 2013; 23: 96–106.

Received: June 4, 2017
Accepted: June 6, 2017